NYSE - Delayed Quote USD

Qiagen N.V. (QGEN)

Compare

41.27

-0.82

(-1.95%)

At close: November 15 at 4:00 PM EST

41.27

0.00

(0.00%)

After hours: November 15 at 5:30 PM EST

Report Name

Direction

Rating

Price Target

Morningstar ?Analyst Report ?10 days ago

Qiagen N.V.: Qiagen Earnings: Strong Postpandemic Diagnostics Results Help Growth Start to Normalize

Direction

Rating

Price Target

Morningstar ?Analyst Report ?3 months ago

Qiagen N.V.: Qiagen Earnings: Small Increases on 2024 Outlook Following Solid Operating Results

Direction

Rating

Price Target

Morningstar ?Analyst Report ?4 months ago

Qiagen N.V.: Qiagen Still Pushing for Higher Growth Than Its End Markets

Direction

Rating

Price Target

Morningstar ?Analyst Report ?6 months ago

Qiagen N.V.: Qiagen Earnings: No Fair Value Estimate Change as Reset Period Continues About as Expected

Direction

Rating

Price Target

Morningstar ?Analyst Report ?9 months ago

Qiagen N.V.: Qiagen Earnings: Management Guides to Weak 2024 That Mildly Affects Our Fair Value Estimate

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Qiagen N.V.: Qiagen Earnings: 2023 Outlook Intact Even as Reset Continues

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Qiagen N.V.: Qiagen Results Resetting After Pandemic

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Qiagen N.V.: Qiagen Earnings: Resetting After COVID-19 Boom Years Looks Likely to Deepen a Bit in 2023

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Qiagen N.V.: Qiagen Earnings: Resetting After COVID-19 Boom Years in Line With 2023 Outlook

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Qiagen N.V.: Qiagen Delivers Decent Q4 Despite Declining COVID-19-Related Sales; Shares Fairly Valued

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Qiagen N.V.: Qiagen Faces Near-Term Challenges, but Long-Term Prospects Look Solid

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Qiagen N.V.: Qiagen Continues to Execute Well in Q3; Shares Mildly Undervalued

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Qiagen N.V.: Reducing Qiagen's Uncertainty Rating In Line With Life Sciences/Diagnostic Peers

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Qiagen N.V.: Qiagen Increases 2022 Outlook on Strong Q2 Trends; Shares Fairly Valued

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Qiagen N.V.: Qiagen's Q1 Helped by Omicron Variant Surge; Shares Fairly Valued

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Qiagen N.V.: Raising Qiagen's FVE on Better-Than-Expected COVID Demand in 2021; Headwinds Look Likely in 2022

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Qiagen N.V.: Qiagen's COVID-19 Tailwinds May Turn Into Headwinds Eventually

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Qiagen N.V.: Qiagen Benefits From Delta Variant Surge in the Third Quarter; Shares Still Overvalued

Direction

Rating

Price Target

Morningstar ?Analyst Report ?3 years ago

Qiagen N.V.: Qiagen Delivers Strong Q2 Preliminary Results but Guides to Weak Rest of 2021 on COVID Trends

Direction

Rating

Price Target

RVTY Revvity, Inc.

109.52

-5.63%

SHC Sotera Health Company

14.31

-4.54%

WAT Waters Corporation

358.46

-4.85%

MYGN Myriad Genetics, Inc.

15.25

-2.74%

A Agilent Technologies, Inc.

127.07

-2.42%

NEOG Neogen Corporation

14.60

-0.27%

LH Labcorp Holdings Inc.

235.21

-1.25%

CRL Charles River Laboratories International, Inc.

187.74

-4.65%

DGX Quest Diagnostics Incorporated

160.44

+2.30%

MTD Mettler-Toledo International Inc.

1,179.58

-4.70%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Qiagen N.V. (QGEN)

Research Reports: QGEN

Qiagen N.V.: Qiagen Earnings: Strong Postpandemic Diagnostics Results Help Growth Start to Normalize

Qiagen N.V.: Qiagen Earnings: Small Increases on 2024 Outlook Following Solid Operating Results

Qiagen N.V.: Qiagen Still Pushing for Higher Growth Than Its End Markets

Qiagen N.V.: Qiagen Earnings: No Fair Value Estimate Change as Reset Period Continues About as Expected

Qiagen N.V.: Qiagen Earnings: Management Guides to Weak 2024 That Mildly Affects Our Fair Value Estimate

Qiagen N.V.: Qiagen Earnings: 2023 Outlook Intact Even as Reset Continues

Qiagen N.V.: Qiagen Results Resetting After Pandemic

Qiagen N.V.: Qiagen Earnings: Resetting After COVID-19 Boom Years Looks Likely to Deepen a Bit in 2023

Qiagen N.V.: Qiagen Earnings: Resetting After COVID-19 Boom Years in Line With 2023 Outlook

Qiagen N.V.: Qiagen Delivers Decent Q4 Despite Declining COVID-19-Related Sales; Shares Fairly Valued

Qiagen N.V.: Qiagen Faces Near-Term Challenges, but Long-Term Prospects Look Solid

Qiagen N.V.: Qiagen Continues to Execute Well in Q3; Shares Mildly Undervalued

Qiagen N.V.: Reducing Qiagen's Uncertainty Rating In Line With Life Sciences/Diagnostic Peers

Qiagen N.V.: Qiagen Increases 2022 Outlook on Strong Q2 Trends; Shares Fairly Valued

Qiagen N.V.: Qiagen's Q1 Helped by Omicron Variant Surge; Shares Fairly Valued

Qiagen N.V.: Raising Qiagen's FVE on Better-Than-Expected COVID Demand in 2021; Headwinds Look Likely in 2022

Qiagen N.V.: Qiagen's COVID-19 Tailwinds May Turn Into Headwinds Eventually

Qiagen N.V.: Qiagen Benefits From Delta Variant Surge in the Third Quarter; Shares Still Overvalued

Qiagen N.V.: Qiagen Delivers Strong Q2 Preliminary Results but Guides to Weak Rest of 2021 on COVID Trends

Related Tickers